Lung Adenocarcinoma Clinical and Molecular Data from the French West Indies

159 patient records from a retrospective, population-based study conducted over 18 months at the University Hospital of Martinique. The data includes clinical, pathological, molecular, and survival information for a Caribbean population with lung adenocarcinoma. Actionable oncogenic drivers were identified in 62% of tumors, and median overall survival was 19.3 months.

Use Cases

• Analyzing the prevalence of targetable oncogenic drivers like EGFR and KRAS based on molecular data mentioned in the description
• Modeling survival outcomes based on clinical and treatment variables described in the study
• Investigating geographic health disparities by comparing this Caribbean cohort data with other populations
• Studying the relationship between PD-L1 expression levels and specific genetic mutations like EGFR

Strengths

• Includes data for 159 patients, providing a specific cohort size for analysis
• Contains integrated clinical, molecular, and survival data, as described in the study methods
• Documents actionable drivers in 62% of tumors with specific mutation rates (e.g., EGFR 33%, KRAS 18%)
• Provides median overall survival figure of 19.3 months

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data reflects a specific 18-month period and single geographic region (French West Indies), which may limit generalizability

Provenance

Source

Régine Marlin, University Hospital of Martinique

Collection Method

18-month, retrospective, population-based study of all consecutive patients diagnosed with lung adenocarcinoma

Time Range

Study conducted over 18 months; specific dates not provided

Freshness

Last updated 2026-05-04 05:34:17; freshness should be verified

Geography

French West Indies (Martinique)